The image contains multiple graphs and panels illustrating the effects of SS1.21 and 3.2.16 on colorectal cancer growth in mice. Panel A shows a line graph of tumor volume in nude mice bearing H C T 116 xenografts treated with vehicle or S S 1.21, with tumor growth monitored over five days. Panel B displays immunoblot assays of tumors harvested four hours after the last dose. Panel C presents a line graph of tumor volumes in mice treated with vehicle, oxaliplatin, S S 1.21, or a combination of oxaliplatin and S S 1.21. Panel D shows a line graph of tumor volumes in B a l b/c mice bearing C T 26 tumors treated with vehicle or S S 1.21. Panel E displays immunoblot assays of tumors harvested four hours after the last dose. Panel F shows immunohistochemistry analysis of tumor sections using anti-C D 31 antibody. Panel G illustrates a timeline of treatment in C 57 B L/6 mice injected with M C 38 cells. Panel H presents a Kaplan-Meier survival analysis of mice treated with vehicle, anti-C T L A-4 antibody, 3.2.16, or both. Panel I shows the mean and individual tumor growth in treated mice. The graphs depict tumor volume changes, survival rates, and the effects of different treatments on tumor growth and mouse survival. All data is approximate.
SS1.21 and 3.2.16 inhibit colorectal cancer growth. (A) Nude mice bearing 150-mm3 HCT116 xenografts were treated with vehicle or SS1.21, and tumor growth was monitored (mean + SD, n = 5); *P < 0.05 by two-way ANOVA. (B) Tumors were harvested 4 h after the last dose, and immunoblot assays were performed. (C) Mice were injected subcutaneously with HCT116 cells and, when a tumor was palpable, were treated with vehicle, Oxa, SS1.21, or Oxa + SS1.21, and tumor volumes were determined (mean + SD, n = 5); *P < 0.05 by two-way ANOVA. (D) Balb/c mice bearing 100-mm3 CT26 tumors were treated with vehicle or SS1.21, and tumor volumes were determined (mean + SD, n = 5); *P < 0.05 by two-way ANOVA with the Bonferroni post-test. (E) Tumors were harvested 4 h after the last dose, and immunoblot assays were performed. (F) Tumor sections from mice treated with vehicle or SS1.21 were analyzed by immunohistochemistry using anti-CD31 antibody. (G) C57BL/6 mice were injected with MC38 cells and treated with vehicle, α-CTLA-4 antibody (200 μg Q3D), 3.2.16 (40 mg/kg BID), or both. (H) Kaplan–Meier analysis of mouse survival is shown. (I) Mean (top panel) and individual (bottom panels) tumor growth are presented. …P < 0.0001 versus vehicle, #P < 0.0001 versus vehicle, **P < 0.0001 versus α-CTLA-4 by two-way ANOVA with Tukey’s post-test. The number of mice with a CR is shown. Scale bar, 500 µm. Oxa, oxaliplatin. Source data are available for this figure: SourceData F4.